HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CRN Surprised When ChromaDex Detailed Elysium Health Litigation During NDI Notification Webinar

Executive Summary

In response to what it says was unexpected airing of ChromaDex' ongoing disputes with Elysium Health, CRN will require speakers at its events to submit materials its review. Chromadex says CRN asked for the type of presentation its chairman made while Elysium Health wasn’t surprised a ChromaDex executive would comment on the litigation.

You may also be interested in...



Split Decision In Breach-of-Contract Battle Of Litigation War Between ChromaDex, Elysium

California federal court jury found both breached contracts: Elysium failed to pay for nicotinamide riboside and pterostilbene it ordered and received, while ChromaDex violated pricing provision in supply agreement.

ChromaDex Loss Down, Tru Niagen Sales Up 22%

Q3 net sales were up 18% and its net loss dropped $3m, the provider of Tru Niagen products containing Niagen, its proprietary form of nicotinamide riboside, reported five days before announcing Tru Niagen stick packs are available under the EX brand in Hong Kong exclusively at A.S. Watson Group’s stores and website.

Framework To Protect NDI Notifications With Master Files Proposed By CHPA, CRN And UNPA

Consumer Healthcare Products Association, Council for Responsible Nutrition and United Natural Products Alliance model proposed NDI-master file framework on US Drug Master File FDA has accepted for decades. System would not be administered by FDA, but the agency’s support is critical for helping manufacturers protect their investments in research for information supporting NDI notifications.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

RS150126

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel